Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Vbi Vaccines Inc CS (NQ: VBIV )

3.150 USD -0.090 (-2.78%)
Official Closing Price Updated: 7:54 PM EST, Jan 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Vbi Vaccines Inc CS

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
VBI Vaccines Announces Progress of Coronavirus Vaccine Program
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today provided an update on the progress... 
From Business Wire News Releases
10 Health Care Stocks With Unusual Options Alerts In Today's Session
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances ... 
Tags Market News BZI/AUOA VBIV
From Benzinga
Why Novartis, BioVie, Esperion And VBI Are Moving Today
Esperion Therapeutics (NASDAQ: ESPR) shares are trading lower after Bank of America Securities downgraded the stock from Buy to Neutral ... 
Tags Market News Movers ESPR
From Benzinga
Why VBI Vaccines Stock Is Vaulting Higher Today
The company reported good news from a study of its hepatitis B vaccine. 
Tags VBIV Market News
From Motley Fool
Thinking about buying stock in VBI Vaccines, Senseonics Holdings, Aemetis, Applied DNA Sciences, or Aphria?
InvestorsObserver issues critical PriceWatch Alerts for VBIV, SENS, AMTX, APDN, and APHA. 
From PR Newswire
VBI Vaccines Announces Publication of Results from a Phase 4 Study of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine in Vaccine
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that results from a... 
From Business Wire News Releases
We Did The Math RYJ Can Go To $59
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
VBI Vaccines Announces European Medicines Agency Acceptance of Marketing Authorization Application (MAA) for 3-Antigen Prophylactic Hepatitis B Vaccine
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the European... 
From Business Wire News Releases
First Week of February 2021 Options Trading For VBI Vaccines (VBIV)
Investors in VBI Vaccines Inc (VBIV) saw new options begin trading this week, for the February 2021 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VBIV options... 
Tags Stocks
From Market News Video
Recent Challenges Demand Innovative Approaches to Surface Disinfections
- FinancialBuzz.com News Commentary 
From PR Newswire
Add Up The Pieces: XBI Could Be Worth $185
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
VBI Vaccines Selects Syneos Health as Commercialization Partner for Prophylactic 3-Antigen Hepatitis B Vaccine
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, and Syneos Health (Nasdaq: SYNH), the leading Contract... 
From Business Wire News Releases
VBI Vaccines to Discuss Hepatitis B Portfolio in Virtual Fireside Chat Hosted by Raymond James
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that members of the VBI... 
From Business Wire News Releases
VBI Vaccines Announces Submission of Biologics License Application to FDA for 3-Antigen Prophylactic Hepatitis B Vaccine
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the submission of a... 
From Business Wire News Releases
70 Biggest Movers From Yesterday
Gainers China Automotive Systems, Inc. (NASDAQ: CAAS) shares surged 174.2% to close at $10.50 on Monday after the company ... 
Tags TBIO NINE AMCI
From Benzinga
46 Stocks Moving In Monday's Mid-Day Session
Gainers China Automotive Systems, Inc. (NASDAQ: CAAS) shares jumped 60% to $6.13 after the company announced a significant ... 
Tags SNDL QS Markets
From Benzinga
VBI Vaccines Announces Submission of Marketing Authorization Application for 3-Antigen Prophylactic Hepatitis B Vaccine to the European Medicines Agency
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the submission of a... 
From Business Wire News Releases
The Daily Biotech Pulse: Aquestive's Positive FDA Meeting, Prevail Awarded Patent, Neuro-Oncology Conference Gets Underway
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ... 
Tags BDSX NEO AQST
From Benzinga
VBI Vaccines Announces Positive Interim Phase 2a Data from VBI-1901 in Recurrent GBM
VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI") a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced Phase 2a (Part B) data... 
From Business Wire News Releases
VBI Vaccines Announces Positive Interim Phase 1b/2a Data for Hepatitis B Immunotherapeutic in Patients with Chronic Infection
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced positive interim... 
From Business Wire News Releases
The Week Ahead In Biotech: The Vaccine Updates, Drug Presentations, And FDA Decisions That Will Move The Markets
Biotech stocks advanced in the week ended Nov. 13 amid a vaccine news flow-induced rally that also lifted the broader market. The ... 
Tags Penny Stocks BNR BMY
From Benzinga
VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at The Liver Meeting® 2020
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the presentation of its... 
From Business Wire News Releases
VBI Vaccines Announces e-Poster Presentation at the Society for Neuro-Oncology (SNO) 2020 Virtual Meeting
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that its abstract... 
From Business Wire News Releases
VBI Vaccines Announces Third Quarter 2020 Financial Results and Provides Corporate Update
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today reported financial results for the... 
From Business Wire News Releases
VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at ID Week 2020™
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the presentation of two... 
From Business Wire News Releases
Interesting VBIV Put And Call Options For December 18th
Investors in VBI Vaccines Inc (VBIV) saw new options begin trading this week, for the December 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VBIV options... 
Tags Stocks
From Market News Video
VBI Vaccines to Present at the H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that members of the... 
From Business Wire News Releases
Why These Coronavirus Vaccine Stocks Crashed in September
In the race for a vaccine, a pause in progress sets you back. 
Tags MRNA VBIV CVAC
From Motley Fool
Add Up The Pieces: LABU Could Be Worth $93
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
VBI Vaccines Announces e-Poster Presentation at The Liver Meeting® 2020
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that its abstract... 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.